A systematic screening study identified 2-phenylindolizine [1] as having significant human cytomegalovirus (HCMV) activity (IC so=7-19 flM). Preliminary mode of action studies on infected cells treated with [1] indicated supression of HCMV-related polypeptides with little effect on the host cells. A series of analogues were synthesized, some of which showed improved HCMV activity although with lower therapeutic intiices than [1]. Several analogues demonstrated significant varicella zoster virus activity, with 2-(4-cyanophenyl)indolizine [5] having an IC so of 5 flM and a therapeutic index of 20 over cell toxicity in the MRC 5 cell line.
Introduction
Humancytomegalovirus (HCMV) is a member of the herpes virus family and is the causative agent of a range of disease symptoms, from mild subclinical disease in otherwise normal healthy individuals to life-threateningdisease in the immunocompromised, for example CMV pneumonitis and retinitis in AIDS patients, and severe disease in bone marrow transplant, solid organ transplant and blood transfusion recipients (Fietze et al., 1994) . It is also a cause of profound deafness, brain damage and death when contracted in utero and has been implicated in restenosis following balloon angioplasty (Speir et al., 1994) . Varicella zoster virus, also a herpesvirus, is the causative agent of varicella (chicken pox), usually a fairly mild disease of children, and herpes zoster (shingles), a more severe recurrence of the infection occurring later in life.
Currently, two compounds are licensed for the treatment of HCMV infections, but use of either is associated with significant drawbacks. The most commonly used, 9-(1,3dihydroxy-2-propoxymethyl)guanine (ganciclovir, GCV, DHPG), although having some effect against CMV retinitis and pneumonia, also has significant myelosuppressive activity Which may lead to neutropenia, resulting in the termination of treatment, and is therefore unsuitable for use in combination with AZT in HIV patients (Faulds and Heel, 1990) . Foscarnet (trisodium phosphonoformate, PFA) is also efficacious in the treatment of HCMV retinitis in the immunocompromised (Jacobsen et aI, 1994) , but is associated with significant renal toxiCity (Bacigalupo et al.,1994) . Furthermore, poor bioavailability necessitates intravenous administration, and both agents require maintainance therapy, exacerbating the problems of toxicity and the emergence of resistance. 9-(2'-hydroxyethoxymethyl)guanine (aciclovir, ACV) is also used for the suppression of HCMV disease in the immunocompromised, and although not associated with any toxic sideeffects it has less potent anti-HCMV activity than GCV.
ACV is, however, the most widely used treatment for VZV disease, but relatively high doses are required to achieve efficacy because of its reduced potency against VZV compared with herpes simplex virus. Other agents, namely valaciclovir (valtrex, VACV), an L-valyl ester prodrug of ACV, and famciclovir [9-(4-acetoxY-3(acetoxymethyl)but-1-yl)-2-aminopurinel, a diacetyl-6-deoxy prodrug of penciclovir [9-(-4-hydroxy-3-methyl-but-1yl)guanine] have recently been licensed for the treatment of shingles, with the goal of achieving higher plasma levels of the active compound by using rapidly metabolized orally administered prodrugs.
In the search for more potent and effective agents for the treatment of HCMV and VZV we discovered interesting activity for a series of indolizines. This discovery was made as a result of a systematic screening programme. Our lead compound was the simple 2-phenylindolizine 1 (Fig. 1) . This paper describes studies on the structureactivity relationships and on the mode of action of the series.
Results

Chemistry
Indolizines have been extensively studied in the chemical literature, and several reviews concerning their synthesis have appeared (Swinbourne et al., 1978; Uchida and Matsumoto, 1976) . The simple 2-phenyl substituted analogues were prepared by the Tschitschibabin reaction involving cyclization of the 2-methyl pyridinium salts (Fig. 2, method A; Tschitschibabin, 1927; Borrows et al., 1946) . This method was not applicable to compounds substituted in the pyridine ring owing to the limited availability of substituted 2-methyl pyridines. A 2+3 cycloaddition route (Kutsuma et al., 1972) was employed extensively for the synthesis of compounds with substituents on the pyridine ring ( Fig. 2, method B ). For 2-phenyl substituted derivatives, 3-phenylcrotonate esters were used as the dipolarophiles. Similar chemistry was used for the preparation of compounds bearing alternative 2-aryl groups, such as thiazole and furyl except that 3-arylacrylates were used as the dipolarophiles (Kakehi and Ito 1974) and the resulting tetrahydroindolizines were oxidised to the required product ( Fig. 2 , method C). The 7nitrile compound 40 was prepared by adaptation of a 1,5ylid cyclisation method originally investigated by Pohjala (1972) (Fig. 2, method D) . In some cases the preparation of the pyridinium salts proved difficult using ethyl bromoacetate, and the trifluoromethylsulphonate of glycolic acid was used. This intermediate was stable but highly reactive and proved convenient for the preparation of the required pyridinium salts.
Although they allowed extensive variation of the substitution pattern, methods Band C required stepwise decarboxylation at the 1 and 3 positions. Decarboxylation at the 3-position could be easily achieved by basic hydrolysis followed by treatment with acid. The 1-carbomethoxy group was inert in these conditions, but was susceptible to acidic hydrolysis and concomitant decarboxylation in refluxing trifluoroacetic acid. Application of these methods allows preparation of either the 1-or the s-substttuted compounds and hence further regioselective functionalisation of the pyrrole ring ( Fig. 3 ). The 3-(1-ribofuranosyl) compound 41 was synthesized as an analogue of the anti HCMV benzimidazole ribosides reported by Townsend's group (Devivar et al., 1994) . The compound was easily prepared by application of the Vorbruggen (1981) methodology normally used in the synthesis of nucleosides ( Fig. 4 ). To our knowledge this is the first ribofuranosyl derivative of an indolizine to be reported. Methods of synthesis, yields and physical organic data are given in table 1.
Structure-activity Relationships
Our initial lead compound, 2-phenyl indolizine 1, demonstrated significant antiviral activity against both VZV and HCMV (Table 2 ). Initially we chose to vary the substituent pattern on the 2-phenyl group as shown in Table 2 . In general, any substitution decreased HCMV activity, whereas several compounds, l.e, 5, 7 and 9, showed improved VZV activity. The 4-nitrile compound 5 demonstrated the best therapeutic index with a Vera cell toxicity of >500 IlM although there was some indication of toxicity at 100 IlM in the MRC 5 cell line indicating a therapeutic index of -20.
Results of more extensive variation of the substituent pattern are shown in Table 3 . As with the substituted 2phenyl analogues it proved easier to obtain significant VZV activity than HCMV activity. Although several compounds showed VZV activity at 10llM or less, most displayed some cell toxicity. The 2-(2-thienyl)indolizine 21, for example, showed VZV activity at 1 IlM but also showed evidence of some morphological changes to the cell line at 20 IlM. The most potent compound against HCMV, 18, with an IC so of 2.7IlM, exhibited slight toxicity at 5 IlM in the MRC 5 cell line even though the toxic concentration in the Vero cell line was >500 IlM. Our original lead 1 therefore demonstrated the best therapeutic index against HCMV with toxicity in the MRC 5 cell line at 200-300 IlM and Vero cell toxicity at 100-500 IlM.
Antiviral activity
The antiviral activities of compounds in a plaque reduction assay (IC s o ) against varicella zoster virus (VZV), human cytomegalovirus (HCMV) and herpes simplex virus type 2 (HSV 2) were determined as described in 'Materials and Experimental Procedures'. Compounds were also assessed for cytotoxicity in Vero cells to determine the concentration of drug that kills 50% of the cells used in the assay (CC so ) . The results of these IC so and CC s o determinations are summarized in Tables 2 and 3 . In some cases, qualitative observations of toxicity to the MRC 5 monolayer in the plaque reduction assay were made, and this fact is noted in the 'Comments' column. We explored the effect of ribosylation on compound 38;
compund 41 is similar to some 1-(ribofuranosyl)benzimidazoles reported to exhibit potent HCMV activity (Oevivar etal., 1994) . However, 41 was found to be cytotoxic. Reagents (i) TFA (ii)NaOH(lO% aq)lMeOH (iii)HCI (iv)PhMe,Heat
Effect on infected cell polypeptides
In a preliminary attempt to address the mode of action, polypeptides in infected cultures were radiolabel/ed with 35S-methionine and the polypeptide profile analysed by SOS-PAGE, to investigate whether there was any difference between cultures infected in the presence and absence of 1 (compound 1, Table 2 ). cells and cells infected with HCMV in the absence of drug or treated with 1 or GCV at a dose equivalent to approximately twice the IC 50 value of the drug (Le. 20 JlM for 1 or 10JlM for GCV) harvested 10 days post-infection. Comparison of uninfected untreated MRC 5 cells with HCMVinfected untreated cells reveals a number of virus-specific bands present only in the infected cell extracts. By comparison with the untreated infected cell extract it is clear that a number of virus-specific protein bands are absent or occur at a low molarity in the presence of either GCV or 1. This effect is less evident at an earlier time-point, i.e, at 7 days (data not shown). Furthermore, there is no detectable inhibitory effect of either drug on the polypeptide profile of uninfected MRC 5 cells, indicating that there is no inhibitory effect on cellular protein synthesis. These results show that, whilst 1 appears to have a specific inhibitory effect on the synthesis of certain viral proteins, it does not affect cellular protein synthesis at the levels tested.
Discussion
Results of plaque reduction assays suggested that a number of the compounds tested had antiviral activity, with generally more potent activity seen against VZV than against HCMV. Whilst we were unable to improve on the specfic activity of compound 1, the mechanism of action is likely to be different from that of GCV.
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Materials and Experimental Procedures: Virology
Cells and virus
Human diploid fibroblast cells (MRC 5, ATCC CCl[171] ) were maintained in Glasgow Modified Eagles Medium (GMEM) containing 10% fetal calf serum. African green monkey kidney cells (Vero, ATCC CCl [81]) were maintained in GMEM containing 10% newborn calf serum. The strain of varicella zoster virus (VZV) used was G 31, from which the published sequence of VZV was obtained (Davison and Scott" 1986) . Stocks of VZV were grown and titrated in MRC 5 cells. The strain of HCMV used was Ad169 (Oram et el., 1982) of which stocks were also grown and titrated in MRC 5 cells. Strain 186 of HSV 2 (Rawls et al., 1968 ) was grown and titrated in Vero cells.
Determination of antiviral activity
Antiviral assays were performed using an adaptation of the plaque reduction assay described by Biron and Elion (1980) . MRC 5 cells were used for HCMV and VZV assays and Vero cells for HSV 2. Assays were overlaid with liquid growth medium containing various concentrations of drug, and in the case of HCMV and HSV 2 carboxymethylcellulose to prevent the formation of secondary plaques. For IC so determination, a dose-response curve was obtained and from this the 50% inhibitory concentration (IC so ) .
Cytotoxicity
The ability of compounds to inhibit cellular (Vero, MRC 5 ) growth was assessed. Compounds were prepared in growth medium to give an appropriate series of 2-fold dilutions, and assayed in triplicate using a 96-well microtitre plate format. Stock solutions of compounds either 10 or 40 mM were made in DMSO and stored at -20 "C. Compound and cells were added to the plate at the same time, to give a final volume of 200 III containing either 1 x 10 4 Vero cells or 5 x 10 3 MRC 5 CI Fig. 6 . Numbering system used for NMR assignments of 41. OH OH HCMV activity of our lead, VZV activity was improved with compounds such as 6. Metabolic labelling of uninfected and HCMV-infected MRC 5 cells in the presence of 1 provided evidence of a Virus-specific mode of action, with no effect on uninfected cell polypeptides. The effect of depletion of virus-specific bands was particularly evident later in infection. The affected polypeptides appeared to include those identified by Mobberley et al.,(1987) as also being inhibited in the presence of GCV, namely the 153kDa major capsid, the 69kDa matrix and the 53kDa DNA-binding proteins. However, the two polypeptide profiles produced in the presence of GCV or compound 1 are not identical, so, whilst this experiment indicates a virus- cells per well. Growth was assessed daily during a period of 3-5 cell doublings (4 days for Vero; 7 days for MRC 5). The number of viable cells was assayed by uptake of the tetrazolium dye MTT. The concentration of compound inhibiting cell replication by 50% was termed the CC 50 (cell toxicity in Tables 2  and 3 ).
Radiolabelling of virus-induced proteins
35S-methionine (1140 Ci rnmor") was obtained from DuPont NEN (Stevenage, UK). Monolayers of MRC 5 cells in 24-well plates were infected with HCMV at a multiplicity of 1 p.f.u. cell" in the presence or absence of drug as required. The infected cells were incubated for either 7 or 10 days at 37 DC prior to harvesting. Twentyfour hours before harvesting, cultures were radiolabelled to detect infected cell polypeptides by the addition of 10~Ci . well-1 of 35S-methionine (Amersham International pic). Cultures were harvested by scraping cells into the medium and washing twice in phosphate-buffered saline (PBS) prior to preparation of samples for analysis by SDS polyacrylamide gel electrophoresis (SDS PAGE).
Materials and Experimental Procedures: Chemistry
Melting points are uncorrected. Flash chromatography was carried out by the method of Still et al. (1978) , except that the columns were slurry-packed. Merck silica Art. no. 9385 was used. NMR spectra were run on a Bruker spectrometer at 200 MHz unless otherwise indicated. Chemical shifts are in 8 ppm relative to TMS.
Method A
A mixture of the picoline (10 mmol) and the required acylbromide (10 mmol) was refluxed in methanol (25 ml) for 3-12 h. The solvent was then removed on a rotary evaporator and the residue washed with ether to give the pyridinium bromide as a white solid. The intermediate was then refluxed in saturated sodium bicarbonate solution (50 ml) for 0.5-1 h. The product precipitated out as the reaction progressed. After cooling, water was added and the solid extracted with dichloromethane (3 x 50 ml). The organic phase was dried over sodium sulphate and evaporated to give the crude indolizine. The product was then purified by recrystallization or flash column chromatography.
MethodB
The substituted pyridine (30 mmol) and either ethyl brornoacetate or methyl-O-trifluoromethylsulphonyl glycolate (30 mmol) (following the method of Beard et al., 1973) were stirred in dichloromethane or tetrahydrofuran (50 ml) for 2-18 h. The solvent was then evaporated on a rotary evaporator and the solid washed with ether to give the pyridinium salt. The intermediate was then stirred in dichloromethane with the relevant proplolate ester (60 mmol) and a base, potassium carbonate (300 mmol) or triethylamine (180 mmol), for 3 days (in some cases refluxing was necessary). The solution was then filtered, dried over sodium sulphate and evaporated. The diester was then purified by flash column chromatography. Decarboxylation was then achieved by refluxing the diester (2 mmol) in 10% sodium hydroxide (5 ml) and methanol (20 ml) for 1 h. This was then evaporated to dryness, trifluoroacetic acid (25 ml) was added and the mixture was refluxed for 6-24 h. The acid was then removed under vacuum and dilute sodium hydroxide added.
The product was then extracted with ethyl acetate (2 x25 ml), dried over sodium sulphate and evaporated. Flash column chromatography then gave the pure product.
MethodC
Triethylamine (120 mmol) in chloroform (15 ml) was added slowly to a mixture of the pyridinium salt (20 mmol) and the acrylate ester (40 mmol) in chloroform (35 ml). The mixture was then refluxed for 24 h. After cooling the solution was washed with water (3 x 50 ml) and dried over sodium sulphate, and the solvent was removed on a rotary evaporator. The dihydroindolizine (3 mmol) was stirred in toluene (30 ml) with lead tetra acetate (3 mmol) for 3 h. This was filtered and evaporated to give the crude product which was purified by flash column chromatography. Decarboxylation was then achieved as in method B.
MethodD
Trifluoromethanesulphonic anhydride (1.2 ml, 7 mmol) (Hatch and Patton, 1954) in dry ether (10 ml) was added dropwise to the 2-phenylallyl alcohol (7 mmol) and pyridine (14 mmol) in dry ether (40 ml) at -50 DC. This mixture was then allowed to warm to room temperature and was stirred overnight before being poured into water (100 ml) and extracted with dichloromethane (3 x 50 mI). Evaporation of the solvent gave a solid which was dissolved in dimethylformamide (25 ml). Potassium carbonate was then added and the mixture refluxed for 6 h. After cooling, ethyl acetate (50 ml) was added. This was washed with water (3 x 100 ml), dried over sodium sulphate and evaporated on a rotary evaporator. Recrystallization or chromatography gave the pure product (110 mg, 0.5 mmol).
8-chloro-2-phenyl-S-(D-ribofuranosyl}-6trifluoromethylindolizine 41
8-Chloro-2-phenyl-6-trifluoromethylindolizine 38 (0.5g, 1.7 mmol) and tri-0-benzyl-1-acetyl-D-ribofuranose (1.7g, 3.4 mmol) in dry acetonitrile (50 ml) were cooled to 0 DC. Tin (IV) chloride (0.2 rnl, 1.7 mmol) was then added and the reaction mixture maintained at 0 DC for 1 h. After stirring at room temperature overnight, the mixture was poured into saturated potassium tartrate solution and extracted with ethyl acetate. This was then dried over sodium sulphate and evaporated to give the crude product which was purified by chromatography (350mg, 0.47mmol). The protected ribofuranosyl compound (350 mg, 0.47 mmol) was dissolved in THF (25ml) and 5M sodium methoxide (0.5 ml, 2.5mmol) was added. The solution was then stirred at room temperature for 1 h. Dowex 50W-X8 (H) (500mg) was then added and stirring was continued until the solution became neutral. Evaporation followed by chromatography gave the product (180 mg, 0.42 mmol) as a 5:1 mixture of ribofuranosides (B:«). The mixture also contained an unidentified ribofuranoside (14%).1H NMR (360 MHz, CDCl a ) f3-anomer s 8.92
(1H, br.q, J=1 Hz, H4), 7.58-7.51 (2H, m, 2H9), 7.48-7.32 (3H, rn, 2H10), 6.94 (1H, br. s, H6), 6.81 (1H, s, H1), 5.24 (1H, d, J=8.4Hz, H1'), 4.58 (1H, rn, H2'), 4.39 (1H, m, H3'), 4.04-3.87 (3H, m, H4' and CH 25'), 2.59 (1H, br,d, J-2Hz, C3' OH), 2.43 (1H, br.d, J-6Hz, C2' OH), 1.71 (1H, br.s, C5'OH). o-Furanoside 8.82 (1H, br,q, J-1Hz, H4), 7.5-7.3 (5H, m, overlapped Ar H), 7.0-6.7 (2H, m, H6 H1), 5.44 (1H, d, J=3.1Hz, H1'), 4.52 (1H, m, H3'), 4.46 (1H, m, H2'), 4.17 (1H, d, J=8Hz, t, J-3.5Hz, H4'), 4.04-3.74 (2H, m, overlapped 5'CH 2 ) , 2.69 (1H, br.d, J-2Hz, C2' OH), 2.51 (1H, br.d, J-7Hz, C3' OH), C5' OH not located. See Fig. 6 for numbering used in assignments. Spin decoupling experiments were used to assist in the signal assignments of the ribose protons. The anomeric configuration of ribose and the linkage between ribose and the indolizine were deduced from 1H_ 1 H nOe NMR data. Signal enhancement observed between H1' and H4' in the major ribofuranoside was diagnostic of a f3 anomeric configuration, and in one of the two minor ribofuranosides, was diagnostic of an ex configuration. In both of these ribofuranosides nO enhancements were observed between H1' and 2H9 and also between H1' and C4-H confirming linkage to C3 of the indolizine.
